These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1010 related items for PubMed ID: 17346863

  • 1. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis.
    KuoLee R, Harris G, Conlan JW, Chen W.
    Vaccine; 2007 May 10; 25(19):3781-91. PubMed ID: 17346863
    [Abstract] [Full Text] [Related]

  • 2. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion.
    Baron SD, Singh R, Metzger DW.
    Infect Immun; 2007 May 10; 75(5):2152-62. PubMed ID: 17296747
    [Abstract] [Full Text] [Related]

  • 3. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.
    Jia Q, Lee BY, Bowen R, Dillon BJ, Som SM, Horwitz MA.
    Infect Immun; 2010 Oct 10; 78(10):4341-55. PubMed ID: 20643859
    [Abstract] [Full Text] [Related]

  • 4. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism.
    Wayne Conlan J, Shen H, Kuolee R, Zhao X, Chen W.
    Vaccine; 2005 Mar 31; 23(19):2477-85. PubMed ID: 15752834
    [Abstract] [Full Text] [Related]

  • 5. Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With Virulent F. tularensis subsp. tularensis.
    Jia Q, Horwitz MA.
    Front Cell Infect Microbiol; 2018 Mar 31; 8():154. PubMed ID: 29868510
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-17 protects against the Francisella tularensis live vaccine strain but not against a virulent F. tularensis type A strain.
    Skyberg JA, Rollins MF, Samuel JW, Sutherland MD, Belisle JT, Pascual DW.
    Infect Immun; 2013 Sep 31; 81(9):3099-105. PubMed ID: 23774604
    [Abstract] [Full Text] [Related]

  • 7. Identification of a live attenuated vaccine candidate for tularemia prophylaxis.
    Mahawar M, Rabadi SM, Banik S, Catlett SV, Metzger DW, Malik M, Bakshi CS.
    PLoS One; 2013 Sep 31; 8(4):e61539. PubMed ID: 23613871
    [Abstract] [Full Text] [Related]

  • 8. Susceptibility of various mouse strains to systemically- or aerosol-initiated tularemia by virulent type A Francisella tularensis before and after immunization with the attenuated live vaccine strain of the pathogen.
    Shen H, Chen W, Conlan JW.
    Vaccine; 2004 Jun 02; 22(17-18):2116-21. PubMed ID: 15149767
    [Abstract] [Full Text] [Related]

  • 9. A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity.
    Sebastian S, Dillon ST, Lynch JG, Blalock LT, Balon E, Lee KT, Comstock LE, Conlan JW, Rubin EJ, Tzianabos AO, Kasper DL.
    Infect Immun; 2007 May 02; 75(5):2591-602. PubMed ID: 17296751
    [Abstract] [Full Text] [Related]

  • 10. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background.
    Chen W, Shen H, Webb A, KuoLee R, Conlan JW.
    Vaccine; 2003 Sep 08; 21(25-26):3690-700. PubMed ID: 12922099
    [Abstract] [Full Text] [Related]

  • 11. Specific antibodies protect gamma-irradiated mice against Francisella tularensis infection.
    Kubelkova K, Krocova Z, Balonova L, Pejchal J, Stulik J, Macela A.
    Microb Pathog; 2012 Sep 08; 53(5-6):259-68. PubMed ID: 22841607
    [Abstract] [Full Text] [Related]

  • 12. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.
    Ray HJ, Cong Y, Murthy AK, Selby DM, Klose KE, Barker JR, Guentzel MN, Arulanandam BP.
    Clin Vaccine Immunol; 2009 Apr 08; 16(4):444-52. PubMed ID: 19211773
    [Abstract] [Full Text] [Related]

  • 13. A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge.
    Jia Q, Bowen R, Sahakian J, Dillon BJ, Horwitz MA.
    Infect Immun; 2013 May 08; 81(5):1550-61. PubMed ID: 23439306
    [Abstract] [Full Text] [Related]

  • 14. Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A.
    Wu TH, Hutt JA, Garrison KA, Berliba LS, Zhou Y, Lyons CR.
    Infect Immun; 2005 May 08; 73(5):2644-54. PubMed ID: 15845466
    [Abstract] [Full Text] [Related]

  • 15. Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization.
    Conlan JW, Shen H, Golovliov I, Zingmark C, Oyston PC, Chen W, House RV, Sjöstedt A.
    Vaccine; 2010 Feb 17; 28(7):1824-31. PubMed ID: 20018266
    [Abstract] [Full Text] [Related]

  • 16. Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.
    Jia Q, Bowen R, Lee BY, Dillon BJ, Masleša-Galić S, Horwitz MA.
    Vaccine; 2016 Sep 22; 34(41):4969-4978. PubMed ID: 27577555
    [Abstract] [Full Text] [Related]

  • 17. Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain.
    Pechous R, Celli J, Penoske R, Hayes SF, Frank DW, Zahrt TC.
    Infect Immun; 2006 Aug 22; 74(8):4452-61. PubMed ID: 16861631
    [Abstract] [Full Text] [Related]

  • 18. Mouse model of oral infection with virulent type A Francisella tularensis.
    KuoLee R, Zhao X, Austin J, Harris G, Conlan JW, Chen W.
    Infect Immun; 2007 Apr 22; 75(4):1651-60. PubMed ID: 17242058
    [Abstract] [Full Text] [Related]

  • 19. Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.
    Richard K, Mann BJ, Qin A, Barry EM, Ernst RK, Vogel SN.
    Clin Vaccine Immunol; 2017 Mar 22; 24(3):. PubMed ID: 28077440
    [Abstract] [Full Text] [Related]

  • 20. Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.
    Richard K, Mann BJ, Stocker L, Barry EM, Qin A, Cole LE, Hurley MT, Ernst RK, Michalek SM, Stein DC, Deshong P, Vogel SN.
    Clin Vaccine Immunol; 2014 Feb 22; 21(2):212-26. PubMed ID: 24351755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.